文献速递乳腺癌

乳房切除术后胸壁放疗对乳腺癌患者5年生活质量的影响:SUPREMO试验

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

SUPREMO试验是一项国际随机对照3期试验,评估中危乳腺癌患者乳房切除术后胸壁放疗与不放疗的5年生活质量。亚组分析提示化疗和前哨淋巴结活检后腋窝清扫可能加重胸壁症状。

要点

  • 其他生活质量领域(手臂症状、体像、疲劳、疼痛、整体生活质量等)无显著差异。

核心结论

  • 中危乳腺癌患者乳房切除术后胸壁放疗在5年时胸壁症状更差,但对其他生活质量领域无显著影响。
  • 亚组分析提示化疗以及前哨淋巴结活检后腋窝清扫可能对胸壁症状有潜在负面影响。

研究设计与样本

  • SUPREMO为国际、平行组、随机对照3期试验,中危乳腺癌患者随机1:1接受胸壁放疗(40-50 Gy,15-25次)或不放疗。
  • 生活质量子研究纳入英国患者,使用EORTC QLQ-C30、QLQ-BR23、体像量表和医院焦虑抑郁量表在基线及1、2、5、10年评估。
  • 国际共招募1691例,随机1679例(放疗组845例,无放疗组834例);英国1233例中989例(80%)同意参与生活质量子研究,947例(96%)返回基线问卷,620例(75%)返回5年问卷。

主要发现

  • 其他生活质量领域(手臂症状、体像、疲劳、疼痛、整体生活质量、躯体功能、焦虑抑郁)无统计学显著差异。

关键数值与推荐

  • 中危乳腺癌定义:pT1-2N1或pT3N0或pT2N0且组织学分级3级或脉管浸润或两者兼有。
  • 胸壁放疗剂量为40-50 Gy,分15-25次。
  • 主要生活质量结局包括整体生活质量、疲劳、躯体功能、胸壁症状、肩臂症状、体像、焦虑和抑郁,采用重复测量混合效应模型分析。

临床怎么用

  • 对于中危乳腺癌乳房切除术后患者,胸壁放疗应权衡胸壁症状风险,尤其对接受化疗或前哨淋巴结活检后腋窝清扫者需谨慎评估。
  • 胸壁放疗未显著影响其他生活质量领域,可作为医患沟通中关于生活质量的参考信息。

局限性

  • 生活质量子研究仅纳入英国患者,可能影响结果外推性。
  • 5年问卷返回率为75%,存在失访偏倚可能。
  • 开放标签设计,患者和研究者未设盲,可能影响主观生活质量报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SUPREMO trial reported adjuvant chest wall radiotherapy had no effect on 10-year overall survival (primary endpoint) in patients with intermediate-risk breast cancer after mastectomy. The quality of life (QOL) substudy of SUPREMO (UK patients only) examines the effects of chest wall radiotherapy in patients with intermediate-risk breast cancer 1 year, 2 years, 5 years, and 10 years after treatment. Here, we report 5-year QOL results (a secondary endpoint), including prespecified subgroup analyses. METHODS: SUPREMO is an international, parallel-group, randomised, controlled, phase 3 trial. Women aged 18 years or older with intermediate-risk breast cancer (defined as pT1-2N1 or pT3N0 or pT2N0 with histological grade 3, or lymphovascular invasion, or both) who had undergone mastectomy (and axillary surgery) were randomly assigned (1:1) to receive chest wall radiotherapy (40-50 Gy in 15-25 fractions) or no radiotherapy. Randomisation was in permuted blocks with varying block length, stratified by centre, without masking of patients or investigators. All UK patients were invited to the QOL substudy. Consenting patients completed validated questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life Core 30-item questionnaire; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer Module, 23 items; Body Image Scale; and Hospital Anxiety and Depression Scale) before randomisation and at 1 year, 2 years, 5 years, and 10 years. Here, we report the prespecified primary QOL outcomes of global QOL, fatigue, physical function, chest wall symptoms, shoulder and arm symptoms, body image, anxiety, and depression in the intention to treat population, using repeated measures mixed-effects models. This trial is registered with the ISRCTN registry, ISRCTN61145589 and is now completed. FINDINGS: Between Aug 4, 2006, and April 29, 2013, SUPREMO recruited 1691 patients internationally, of whom 1679 were randomly assigned to receive chest wall radiotherapy (n=845) or not (n=834). Of 1233 patients from UK centres (619 in the chest wall radiotherapy group and 614 in the no chest wall radiotherapy group), 989 (80%) consented to the QOL substudy: 947 (96%) of 989 returned baseline questionnaires and 620 (75%) of 832 patients returned the expected year-5 questionnaires. Chest wall symptoms were worse with chest wall radiotherapy (effect estimate 1·99 [95% CI 0·36-3·62]; p=0·017) with an improvement between years 1, 2, and 5. Chemotherapy was associated with less improvement over time (effect estimate 2·97 [95% CI 0·24-5·71]; p=0·033) but without interaction with chest wall radiotherapy. No statistically significant differences were observed in other QOL domains (arm symptoms, body image, fatigue, pain, overall QOL, physical functioning, or anxiety and depression). In the subgroup analyses, patients who had a sentinel lymph node biopsy followed up by an axillary lymph node clearance with chest wall radiotherapy had worse chest wall symptoms than those having a single axillary operation (difference chest wall radiotherapy vs no chest wall radiotherapy -5·29 [95%CI -8·53 to -2·05]; p=0·0015). INTERPRETATION: The 5-year QOL findings showed worse chest wall toxicity and no effect on other QOL domains. The subgroup analyses suggested a potential negative effect of chemotherapy and axillary clearance after sentinel node biopsy. FUNDING: UK Medical Research Council, National Institute for Health and Care Research, European Organisation for Research and Treatment of Cancer, Edinburgh Trustees of Breast Cancer Institute in Edinburgh and the Edinburgh Cancer Centre NHS Endowment funds, The Dutch Cancer Society, Trustees of the Hong Kong and Shanghai Banking Corporation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Velikova G, Russell NS, Williams LJ, et al. Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 42508432. doi:10.1016/S1470-2045(26)00122-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。